Cargando…
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
In patients with disseminated malignant melanoma an optimal method of immunization with irradiated tumour cells was developed by reference to an in vitro assay for circulating specific serum inhibitors of cell mediated cytotoxicity. This immunization protocol consisted of the intradermal inoculation...
Autores principales: | Currie, G. A., McElwain, T. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1975
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009407/ https://www.ncbi.nlm.nih.gov/pubmed/1164466 |
Ejemplares similares
-
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
por: Hedley, D. W., et al.
Publicado: (1978) -
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990) -
Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy.
por: Selby, P. J., et al.
Publicado: (1980) -
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
por: Newlands, E. S., et al.
Publicado: (1976) -
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)